Detalhe da pesquisa
1.
Biology and Clinical Implications of the 19q13 Aggressive Prostate Cancer Susceptibility Locus.
Cell
; 174(3): 576-589.e18, 2018 07 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-30033361
2.
Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer.
N Engl J Med
; 386(12): 1132-1142, 2022 03 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-35179323
3.
Extended Safety and Tolerability of Darolutamide for Nonmetastatic Castration-Resistant Prostate Cancer and Adverse Event Time Course in ARAMIS.
Oncologist
; 2024 Feb 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-38394384
4.
Screening history and risk of death from prostate cancer: a nested case-control study within the screening arm of the Finnish Randomized Study of Screening for Prostate Cancer (FinRSPC).
Cancer Causes Control
; 35(4): 695-703, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38063980
5.
Which men benefit from prostate cancer screening? Prostate cancer mortality by subgroup in the European Randomised Study of Screening for Prostate Cancer.
BJU Int
; 2024 May 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-38725182
6.
Expected impact of MRI-targeted biopsy interreader variability among uropathologists on ProScreen prostate cancer screening trial: a pre-trial validation study.
World J Urol
; 42(1): 217, 2024 Apr 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-38581590
7.
Prostate Cancer Screening With PSA, Kallikrein Panel, and MRI: The ProScreen Randomized Trial.
JAMA
; 331(17): 1452-1459, 2024 05 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-38581254
8.
Prostate cancer incidence in men with prostate-specific antigen below 3 ng/mL: The Finnish Randomized Study of Screening for Prostate Cancer.
Int J Cancer
; 152(4): 672-678, 2023 02 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-36056577
9.
Antidiabetic drugs, glycemic control and risk of benign prostatic hyperplasia.
Prostate
; 83(3): 246-258, 2023 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36325820
10.
Nonmetastatic, Castration-Resistant Prostate Cancer and Survival with Darolutamide.
N Engl J Med
; 383(11): 1040-1049, 2020 09 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-32905676
11.
Testosterone replacement therapy is not associated with increased prostate cancer incidence, prostate cancer-specific, or cardiovascular disease-specific mortality in Finnish men.
Acta Oncol
; 62(12): 1898-1904, 2023 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-37971326
12.
Missingness in the expanded prostate cancer index short form (EPIC-26) - prevalence, patterns, and explanatory factors.
Health Qual Life Outcomes
; 21(1): 89, 2023 Aug 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-37580759
13.
Posterior quadratus lumborum block versus epidural analgesia for postoperative pain management after open radical cystectomy: A randomized clinical trial.
Acta Anaesthesiol Scand
; 67(3): 347-355, 2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36547262
14.
Prostate cancer-related sexual dysfunction - the significance of social relations in men's reconstructions of masculinity.
Cult Health Sex
; : 1-15, 2023 Sep 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-37665659
15.
Anti-epileptic drugs and prostate cancer-specific mortality compared to non-users of anti-epileptic drugs in the Finnish Randomized Study of Screening for Prostate Cancer.
Br J Cancer
; 127(4): 704-711, 2022 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-35505251
16.
Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer.
N Engl J Med
; 380(13): 1235-1246, 2019 03 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-30763142
17.
Improved renal cancer prognosis among users of drugs targeting renin-angiotensin system.
Cancer Causes Control
; 33(2): 313-320, 2022 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-34921656
18.
Lower Urinary Tract Symptoms and Mortality among Finnish Men: The Roles of Symptom Severity and Bother.
J Urol
; 207(6): 1285-1294, 2022 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-35470712
19.
Population-based randomized trial of screening for clinically significant prostate cancer ProScreen: a pilot study.
BJU Int
; 130(2): 193-199, 2022 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-34958531
20.
The expanded prostate cancer index composite short form (EPIC-26) for measuring health-related quality of life: content analysis of patients' spontaneous comments written in survey margins.
Qual Life Res
; 31(3): 855-864, 2022 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-34291363